AzTrials
AzTrials

PainTRAKC18NCT02694692

Trial of Repeated Analgesia With Kangaroo Care - 18 Month Follow-up

An observational study of Pain and Development, run by IWK Health Centre at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The primary aim for this study is to determine if maternal Kangaroo Care (KC) provided during painful procedures in early life will mitigate stress release and will improve neurobehavioural outcomes in infants, decrease subsequent pain response, and enhance maternal-child interaction beyond the period of… Read more about this study

Who is it for?
Ages 2 to 20 months
Conditions the study is for
Pain, Development
What is being tested?
Vaccinations at 2, 6, 12 and 18 month and Neurodevelopment assessment at 18 corrected age
How many people
159 participants
Where
1 siteCanada
Study dates
Jan 2015to Oct 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 20 months
  • All sexes
  • No healthy volunteers
  • Child

Study population: Eligible parents of TRAKC infants who have provided consent will be invited back to an IWK clinic for follow-up visits at a convenient date within +/- 2 weeks of 2, 6, 12 and 18 month CA for their vaccinations as well as at 18 month corrected age for a Bayley Scales of Infant Development (BSID-III).

Who may be able to join

  • Participation in the original TRAKC trial (Born less than 36 6/7 weeks gestational age and were stable enough to be held in KC)
  • Participants live within 100 km from hospital or are willing to routinely return to the IWK for follow-up
  • Exclusion criteria from the initial TRAKC trial included major congenital anomalies, receiving narcotics, or surgery.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Marsha Campbell-Yeo, RN, NNP, PhD contact

902-470-7455

marsha.campbellyeo@iwk.nshealth.ca

Canada1 site, 1 recruiting
  • IWK Health Centre

    Halifax, Nova Scotia, B3K6R8

    Marsha Campbell-Yeo, RN, NNP, PhD, 902-470-7455, marsha.campbellyeo@iwk.nshealth.ca

    Justine Dol, MSc, 902-470-6769, justine.dol@iwk.nshealth.ca

    Recruiting

Other trials in Canada

About this study

The primary aim for this study is to determine if maternal Kangaroo Care (KC) provided during painful procedures in early life will mitigate stress release and will improve neurobehavioural outcomes in infants, decrease subsequent pain response, and enhance maternal-child interaction beyond the period of hospitalization.

Read the detailed description

Background: Infants in the Neonatal Intensive Care Unit receive an average of 7 painful procedures daily yet less than half receive interventions to manage pain. Importantly, there are adverse long-term effects associated with untreated pain. Moreover, the developmental trajectory of an infant born preterm is further compromised by prolonged periods of separation from their mothers during their hospital stay that also impacts mother-infant relationships. Thus, there is a crucial need to minimize procedural pain and associated consequences. Kangaroo Care (KC) is an effective strategy for reducing procedural pain and promoting mother-infant interactions in infants demonstrated in multiple clinical trials and systematic reviews. Not known is the impact of consistent KC for pain on long term outcomes. The primary aim for this study is to determine if maternal KC provided during painful procedures in early life will mitigate stress release and will improve neurobehavioural outcomes in infants, decrease subsequent pain response, and enhance maternal-child interaction beyond the period of hospitalization.

Research Design: Using a randomized clinical trial follow up design, mother-infant dyads taking part in the current CIHR and NSHRF-funded TRAKC trial (randomized to one of three interventions during all routine clinically necessary painful procedures for the duration of their initial neonatal intensive care unit hospital stay (KC/placebo; sucrose alone, considered to be standard care; or KC/ sucrose) will be compared on neurobehavioural outcomes up to 18 months.

Procedure: Eligible mother-infant dyads will be contacted prior to routine 2, 6, 12 and 18 month clinic visits where during these visits, infants will undergo an immunization and naturalistic observations will be recorded. Coders blinded to the study will score pain intensity and maternal comforting behavior using validated measures. At the 18 month visit, trained medical assessors blind to group assignment will perform the primary outcome measure, Bayley Scales of Infant Development (3rd ed) (BSID-III).

Outcomes: The investigators hypothesize that infants from the current TRAKC trial who were assigned to either KC group (alone or in combination with sucrose) when compared to those infants in the sucrose alone group will have: Primary outcome: H1. higher scores on the BSID-III at 18 months corrected postnatal age. Secondary outcomes: H2. higher scores in socio-affective development (Social-Emotional axis of the BSID-III and the Brief Infant Toddler Social Emotional Assessment (BITSEA); H3. lower scores on Negative Affectivity, higher scores on Surgency/Extraversion and Effortful Control as measured by the Early Childhood Behavior Questionnaire (ECBQ); H4. lower pain scores measured using the Modified Behavioral Pain Scale (MBPS) at 2, 6, 12, and 18 month;. H5. higher maternal infant interaction scores measured using Measure of Adult and Infant Soothing and Distress Scale (MAISD) at 2, 6, 12 and 18 months.

Sample size: The sample size is 159 mother-infant dyads at 18 months.

Benefits of the Research Project: New evidence about the long-term impact of early KC provided during early painful procedures is important to the effective management of procedural pain and development in vulnerable infants. By fully integrating mothers and families as active participants, it will have direct implications regarding the improvement of outcomes of at-risk newborns, not only for their immediate physiological stability and later development, but also their families, and the health care system in general.

Conditions
Pain, Development
Being tested
Vaccinations at 2, 6, 12 and 18 month, Neurodevelopment assessment at 18 corrected age
Medical subject headings
Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vaccinations at 2, 6, 12 and 18 monthProcedure or surgery

    Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.

  • Neurodevelopment assessment at 18 corrected ageBehavioural

    During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.

Study groups in NCT02694692
Study groupRoleWhat they receive
Follow-upNo further interventions are planned for this trial and the three pain management interventions from the original study (NCT01561457) will remain our comparison groups (Kangaroo Mother Care alone, Sucrose alone, and Kangaroo Mother Care \& Sucrose). All participants will be invited to back to the IWK Health Centre to receive their Vaccinations at 2, 6, 12 and 18 month time points as well as for their Neurodevelopment assessment at 18 corrected age (BSID-III).
Receives: Procedure: Vaccinations at 2, 6, 12 and 18 month; Behavioral: Neurodevelopment assessment at 18 corrected age

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bayley Scales of Infant Development (BSID-III)

    The Bayley Scales of Infant and Toddler Development (3rd edition; BSID-III) , the most widely used standardized assessment of early milestone-based development in young children, evaluates five domains related to development of infants from 1 to 42 months of age: cognitive, language, motor, adaptive behaviour, and social-emotional.

    Measured: 18 months corrected postnatal age

Secondary outcomes (4)
  1. Brief Infant Toddler Social Emotional Assessment (BITSEA)

    The BITSEA is the Brief form of the Infant Toddler Social and Emotional Assessment, which covers domains of behaviour. The BITSEA is effective for children aged 12 to 36 months.

    Measured: 18 month corrected postnatal age

  2. Early Childhood Behaviour Questionnaire (ECBQ)

    The ECBQ was developed and validated to measure temperament in toddlers between 18 and 36 months of age and has shown adequate levels of reliability and validity. The 201-item parent-report questionnaire assesses 18 dimensions of temperament.

    Measured: 18 month corrected postnatal age

  3. Modified Behavioral Pain Scale (MBPS)

    The MBPS, a well-validated acute pain scale used to measure procedural pain, including needle related pain in infant populations, starting at 2 months. The MBPS assesses pain in terms of three observable behaviours: facial expressions, cry, and body movement.

    Measured: 2, 6, 12, and 18 months

  4. Measure of Adult and Infant Soothing and Distress Scale (MAISD)

    This is a behavioural measure developed to assess adult and infant behaviour during medical procedures.

    Measured: 2, 6, 12, and 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Feb 2016 (estimated)
  2. Study startJan 2015
  3. Primary completionOct 2017 (estimated)
  4. Study completionOct 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
159 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02694692
Sponsor's protocol ID
1017737
Acronym
TRAKC18
Status last verified
Mar 2017
First submitted
24 Feb 2016
Last updated
8 Mar 2017
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Pain and Development, run by IWK Health Centre at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Marsha Campbell-Yeo, RN, NNP, PhD (902-470-7455, marsha.campbellyeo@iwk.nshealth.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bayley Scales of Infant Development (BSID-III) (time frame: 18 months corrected postnatal age). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Mar 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in